In the latest trading session, 0.47 million Verona Pharma Plc ADR (NASDAQ:VRNA) shares changed hands as the company’s beta touched 0.44. With the company’s most recent per share price at $29.31 changing hands around $1.27 or 4.53% at last look, the market valuation stands at $2.38B. VRNA’s last price was a premium, traded about 1.64% off its 52-week high of $28.83. The share price had its 52-week low at $11.39, which suggests the last value was 61.14% up since then. When we look at Verona Pharma Plc ADR’s average trading volume, we note the 10-day average is 0.95 million shares, with the 3-month average coming to 1.50 million.
Analysts gave the Verona Pharma Plc ADR (VRNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VRNA as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Verona Pharma Plc ADR’s EPS for the current quarter is expected to be -0.5.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
Instantly VRNA is in green as seen in intraday trades today. With action 6.51%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 47.44%, with the 5-day performance at 6.51% in the green. However, in the 30-day time frame, Verona Pharma Plc ADR (NASDAQ:VRNA) is 18.76% up. Looking at the short shares, we see there were 10.7 million shares sold at short interest cover period of 8.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 36, meaning bulls need an upside of 18.58% from its recent market value. According to analyst projections, VRNA’s forecast low is 26 with 38 as the target high. To hit the forecast high, the stock’s price needs a -29.65% plunge from its current level, while the stock would need to tank 11.29% for it to hit the projected low.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
Data shows that the Verona Pharma Plc ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 77.85% over the past 6 months, a -187.50% in annual growth rate that is considerably lower than the industry average of 17.40%.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 1.94M. 6 analysts are of the opinion that Verona Pharma Plc ADR’s revenue for the current quarter will be 4.93M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.36%. The 2024 estimates are for Verona Pharma Plc ADR earnings to decrease by -188.89%.
VRNA Dividends
Verona Pharma Plc ADR is expected to release its next quarterly earnings report on 2024-Aug-08.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.90% of Verona Pharma Plc ADR shares while 91.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.48%. There are 91.76% institutions holding the Verona Pharma Plc ADR stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 9.4566% of the shares, roughly 7.63 million VRNA shares worth $110.37 million.
NEA MANAGEMENT COMPANY, LLC holds the second largest percentage of outstanding shares, with 6.9193% or 5.58 million shares worth $80.76 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2024 were Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund. With 1.15 shares estimated at $33.38 million under it, the former controlled 2.21% of total outstanding shares. On the other hand, Federated Hermes Kaufmann Small Cap Fund held about 1.91% of the shares, roughly 990.0 shares worth around $28.86 million.
